| 吕筠,李立明,曹卫华,詹思延,胡永华.苯那普利上市后流行病学监测[J].Chinese journal of Epidemiology,2004,25(5):412-416 |
| 苯那普利上市后流行病学监测 |
| Postmarketing surveillanc on Benazepril |
| Received:July 18, 2003 |
| DOI： |
| KeyWord: 血管紧张素转换酶抑制剂 药物监测 不良反应 |
| English Key Word: Angiotensin-converting anzyme inhibitors Product surveillance Adverse drug reaction |
| FundProject:国家“九五”科技攻关基金(96-906-02-05) |
| Author Name | Affiliation | | Lv Jun | Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100083, China | | Li Li-ming | 中国疾病预防控制中心 | | Cao Wei-hua | Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100083, China | | Zhan Si-yan | Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100083, China | | Hu Yong-hu | Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100083, China |
|
| Hits: 3320 |
| Download times: 1169 |
| Abstract: |
| 目的: 了解苯那普利在一般高血压患者中长期应用的药效及安全性。方法: 对上海市某社区1831例原发性高血压患者进行为期3年的药物上市后流行病学监测。结果: 3年随访74.3%的患者坚持服药, 且具有理想的服药依从性。用药3年后, 按规定服药者的收缩压达标率为75.7%, 舒张压达标率为87.4%, 总达标率为71.5%。总体收缩压水平较服药前降低了近15mm Hg(1mmHg=0.133kPa), 舒张压降低了约10mmHg, 脉压降低了近5mmHg。用药期间, 未见有严重不良反应发生。咳嗽是该药主要的一种不良反应。3年累积咳嗽发生率, 女性达23.6%, 高于男性的18.8%。结论: 苯那普利应用于一般高血压患者群体时, 具有较好的长期效果和安全性。 |
| English Abstract: |
| Objective: To investigate the long-term effect, safety and tolerability of benazepril in general hypertensive patients. Methods: We conducted a three-year community-based postmarketing surveillance on benazepril among 1831 essential hypertensive patients(age range from 35 to 88 years) in Shanghai. Results: 74.3% of patients persisted in medication taking and were with optimal compliance in a 3-year-follow-up program. Among those taking medication as prescribed after 3 years, 75.7% of them attained systolic blood pressure(SBP) target level of 140 mm Hg(1 mm Hg = 0.133 kPa), 87.4% attained diastolic blood pressure(SBP) target level of 90 mm Hg, and 71.5% attained total target level of 140/90 mm Hg. The reductions were approaching 15 mm Hg for SBP, 10 mm Hg for DBP, 10 mm Hg for DBP, and 5 mm Hg for pulse pressure(PP) during the 3 year period. No serious adverse drug reactions(ADRs) were detected during the 3 years follow-up. Cough was the most common ADR. The cumulative incidence of benazepril was safe and tolerable when applied in hypertensive patients. |
|
View Fulltext
Html FullText
View/Add Comment Download reader |
| Close |
|
|
|